nash semaglutide essence trial for MASH in #ESSENCE #Semaglutide hits both primary endpoints in trial 📍62.9% resolved steatohepatitis (vs 34.3% placebo) 📍36.8% showed fibrosis improvement (vs 22.4% placebo) 📍Combined response: 32.7% vs The Therapeutic Potential of PetCare Strength:10mg

nash semaglutide essence trial for MASH in #ESSENCE #Semaglutide hits both primary endpoints in trial 📍62.9% resolved steatohepatitis (vs 34.3% placebo) 📍36.8% showed fibrosis improvement (vs 22.4% placebo) 📍Combined response: 32.7% vs The Therapeutic Potential of PetCare Strength:10mg

The Therapeutic Potential of GLP-1 Receptor Agonists in the Management of Hidradenitis Suppurativa: A Systematic Review of Anti-Inflammatory and Metabolic Effects - PMC

Key deadlines to consider: State-Specific Time Frames : The statute of limitations can vary significantly depending on the state

PetCare

Strength:10mg

Because I think one of the things you hear about GLP-1 drugs, especially when it comes to weight, is that once you stop the medications, a significant percentage of people will regain that weight